Suppliers / Yung Shin Pharm. Ind

Yung Shin Pharm. Ind

Taiwan Updated 9 July 2026

Yung Shin Pharm. Ind is a finished-dose manufacturer based in Taiwan. It appears in 1 regulatory filing across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by EMA. Its most recent recorded inspection, by US FDA, closed on 22 October 2019 as VAI.

0
active US DMFs
0
valid CEPs
2
registered plants 1 with an FDA FEI number
1
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 22 October 2019 VAI US FDA
  • 27 July 2018 VAI US FDA
  • 8 May 2014 NAI US FDA
  • 16 August 2013 NAI US FDA
  • 30 April 2012 VAI US FDA
  • 5 February 2010 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Taiwan, Taiwan 3002808536
Tachia, Taiwan Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
NPRA (MY) 1 None
EMA None 1

Comparing suppliers?

Choose your molecules and target markets. Yung Shin Pharm. Ind comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 22 October 2019.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates